By Jessica Hagen , Executive Editor | December 18, 2025 | 1:35 PM

Photo: Kseniya Ovchinnikova/Getty Images

At-home health testing platform Ash is expanding its partnership with weight-loss company Noom to bring Noom’s Proactive Health Microdose GLP-1Rx Program to market.

Noom’s program, launched in August, combines personalized microdoses of GLP-1 medications, biomarker testing and a digital healthy habits platform. Users will be able to gain insights into 17 biomarkers linked to current and future health.

Ash is a device-agnostic company that integrates devices into its framework for partners like Noom.

Through the partnership, Ash will provide the at-home testing infrastructure for Noom’s program, enabling the collection and management of biomarker data that gives users insights into markers associated with chronic disease risk and aging.

The FDA-cleared blood lancet Tasso+ device will be included in Noom’s biomarkers test kit, which allows for blood sample collection. The company said the lancet collects whole wet blood samples, making it ideal for patients who are not comfortable using traditional lancets or needles.

"The future of longevity depends on seamlessly bridging the digital patient experience with best-in-class physical diagnostic tools," Kyle Waters, CPO of Ash, said in a statement.

"At-home health testing only works at scale when the underlying infrastructure is frictionless and clinically rigorous. Ash manages the logistics, device integration and data integrity behind the scenes so partners like Noom can focus on translating biomarker data into meaningful health change."

THE LARGER TREND

Earlier this month, Castlight Health and Noom announced exclusively through MobiHealthNews that Noom’s weight-loss, diabetes and GLP-1-related programs, including Noom Weight, Noom Diabetes and Noom Med, will be integrated into Castlight’s app and healthcare navigation services beginning in the first quarter of 2026.

In April, Noom entered into an agreement with Eli Lilly’s LillyDirect pharmacy provider Gifthealth to help improve access to FDA-approved Zepbound (tirzepatide) single-dose vials for Noom’s members with an on-label prescription from a doctor.​

In February, the weight loss company laid off a portion of its staff. At the time, a spokesperson told MobiHealthNews that the move was related to "a revenue mix shift within the Noom business towards our fast-growing GLP-1-related products, including Noom GLP-1Rx and Noom GLP-1 Companion."

Tags: